Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

(Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI ® (pegcetacoplan) as ...

We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for ...

JPMorgan raised the firm’s price target on Apellis (APLS) to $37 from $35 and keeps an Overweight rating on the shares. The firm updated the ...

In other recent news, Apellis Pharmaceuticals reported its first-quarter earnings for 2025, revealing an earnings per share (EPS) of -$0.74, which fell short of the forecasted -$0.34.

Get the detailed quarterly/annual income statement for Apellis Pharmaceuticals, Inc. (APLS). Find out the revenue, expenses and profit or loss over the last fiscal year.